The announcement of an exclusive licensing agreement for a narcolepsy treatment is significant for Harmony Biosciences. It not only expands their product portfolio but also strengthens their position in the biopharmaceutical sector, particularly in the treatment of sleep disorders. This positive news is likely to increase investor confidence in HRMY, leading to a short-term uptick in its stock price.